Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum ...

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp.(CHRO) to combine Ligand's wholly owned subsidiaries, Pelthos ...

These fluorination and ligand-exchange reactions lead to atomic layer controlled etching. This ALE approach is extendible to other materials besides metal oxides. Our current work has demonstrated the ...

Under the agreement, Ligand’s wholly owned subsidiaries ... the combined company will trade on the NYSE American exchange under the ticker PTHS. Channel, a non-opioid pain treatment therapeutics ...

and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ... Inc. and trade on the NYSE American exchange under the ticker PTHS. The combined company will ...